The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, ...

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

If you are facing a recurrence of classic Hodgkin lymphoma, or you have become resistant to your treatment, there is some good news that may help. The FDA approved Keytruda (pembrolizumab), which is ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Adding pembrolizumab to modern, high-quality chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer.

Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

In contrast, KEYNOTE-826 3 indicated slightly higher HRs for pembrolizumab when added to chemotherapy without bevacizumab. Given that bevacizumab has shown a proven overall survival benefit when added ...